Updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening
March 7th 2018In this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.
Study Demonstrates a Common Genetic Etiology for LCH, AML, and MF
March 5th 2018Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis.
Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck Cancer
February 20th 2018An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.
Reduced RT Feasible in Chemo-Sensitive HPV-Associated Head and Neck Cancer
February 19th 2018Patients with human papillomavirus–associated head and neck cancers who respond well to induction therapy can receive substantially lower doses of radiation and still achieve good safety and efficacy outcomes, according to a new phase II trial.
Polyp Burden Drops With Sulindac/Erlotinib Combo in FAP
February 15th 2018Patients with familial adenomatous polyposis have an increased risk for colorectal polyps and cancer; however, treatment with a combination of sulindac and erlotinib reduced their colorectal polyp burden by more than two thirds.
Coffee May Carry Cancer Warning
February 13th 2018Coffee may soon contain a warning that it contains acrylamide, a known carcinogen. A recent lawsuit filed by the nonprofit Council for Education and Research in Toxics alleges that coffee shops in California “failed to provide clear and reasonable warning” that their product could expose people to acrylamide.
Unique Blood Test May Help Detect Eight Cancers
February 6th 2018A new multianalyte test simultaneously evaluates levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood, offering clinicians and patients a potentially affordable way of detecting cancer at an earlier stage.